A leading medical journal published an editorial asserting that the rise of personalized medicine, which tailors treatments to an individual's genetic profile, will inevitably lead to a widening of health disparities. The argument is that the advanced diagnostic tests and therapies inherent to personalized medicine will be prohibitively expensive, accessible only to the wealthy, thus exacerbating the divide between those who can afford cutting-edge care and those who cannot. However, the journal's editor added a caveat, acknowledging that some might argue that economies of scale, driven by widespread adoption, could eventually make these treatments affordable for all.
Correct: E
The editorial argues that personalized medicine will 'inevitably lead to a widening of health disparities' because treatments will be 'prohibitively expensive, accessible only to the wealthy'. It acknowledges a counter-argument (economies of scale could make it affordable). The question asks for the main point.
Option (E) best captures the main point. The editorial *warns* about the *risk* of exacerbating health disparities 'without proactive measures to address cost' (implied by the 'prohibitively expensive' and 'accessible only to the wealthy' argument). The caveat about economies of scale further reinforces this: it's not saying it *will* definitely happen regardless, but that it's the likely outcome *if* costs aren't managed. The core message is a cautionary one about the financial implications and their impact on equity.
(A) While advocating for subsidies might be a logical follow-up to the editorial's points, it's not explicitly stated as the primary purpose of *this specific text*. The text is diagnostic/predictive, not prescriptive in its main point.
(B) This describes the *topic* of the editorial (financial barriers) but not its *main point* or overall message. The point is not just to discuss barriers, but to predict an outcome based on those barriers.
(C) This is close, but 'ethical dilemma' is a broader concept. The editorial specifies the *nature* of the dilemma as exacerbating health disparities due to cost, which (E) captures more precisely.
(D) While the editorial might challenge that assumption, its primary focus is on the specific case of personalized medicine and its potential negative equity consequences, not a general philosophical statement about all technological advancements.